Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.59 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TAS2R8 | Q9NYW2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938269 | 0.91 | IGF1R (0.61) | IGF1RTAS2R8 | |
| SCHEMBL2935141 | 0.90 | MCHR1 (0.47) | IGF1RSLC22A12MCHR1CYP3A4 | |
| SCHEMBL2938825 | 0.90 | IGF1R (0.60) | IGF1RMCHR1 | |
| SCHEMBL2936443 | 0.90 | IGF1R (0.67) | IGF1R | |
| SCHEMBL2943931 | 0.88 | IGF1R (0.46) | IGF1RSLC22A12MCHR1CYP3A4TAS2R8 | |
| SCHEMBL2941315 | 0.86 | IGF1R (0.64) | IGF1RTAS2R8 | |
| SCHEMBL2935169 | 0.85 | IGF1R (0.62) | IGF1R | |
| SCHEMBL2936417 | 0.83 | IGF1R (0.59) | IGF1R | |
| SCHEMBL2942305 | 0.83 | IGF1R (0.53) | IGF1RCYP3A4 | |
| SCHEMBL2942422 | 0.83 | IGF1R (0.68) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825115-B2 | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| EP-1599464-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2010-09-22 | — | — | EP | disclosed |
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-7354933-B2 | Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate | AVENTIS PHARMA SA (FR) | 2008-04-08 | — | — | US | disclosed |
| EP-1599464-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-11-30 | — | — | EP | disclosed |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-09 | — | — | US | disclosed |
| WO-2004070050-A2 | CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKG1, PRKACA, CMPK1 | IGF1R 1595/4885SLC22A12 3963/4885MCHR1 4505/4885 |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | PRKG1, PRKACA, PRKCA | IGF1R 962/4885SLC22A12 3835/4885MCHR1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.